MCM
ARCT icon

MAI Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

MAI Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-465
Closed -$3.59K – 2245
2026
Q1 		$3.59K Buy
465
+84
+22% +$613 ﹤0.01% 3675
2025
Q4 		$2.34K Hold
381
– – ﹤0.01% 3375
2025
Q3 		$7.02K Hold
381
– – ﹤0.01% 2885
2025
Q2 		$4.96K Hold
381
– – ﹤0.01% 3048
2025
Q1 		$4.04K Hold
381
– – ﹤0.01% 2786
2024
Q4 		$6.47K Buy
+381
New +$7.17K ﹤0.01% 2681

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

MAI Capital Management's ARCT Position: Q2 2026 in Review

MAI Capital Management sold out of Arcturus Therapeutics (ARCT) in Q2 2026, closing a stake of 465 shares — an estimated $3.59K sold.

MAI Capital Management first reported a position in ARCT in Q4 2024 and held it in 6 quarters. The position peaked at $7.02K in Q3 2025. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • MAI Capital Management reported no remaining Arcturus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 465 Arcturus Therapeutics shares in Q2 2026, an estimated $3.59K.
  • MAI Capital Management first reported a position in Arcturus Therapeutics in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Arcturus Therapeutics position peaked at $7.02K in Q3 2025.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.